[1]刘 洁,王源源,郭志刚,等.FEN1抑制剂SC13逆转MCF-7/ADR细胞的耐药性研究[J].南京师大学报(自然科学版),2024,(04):77-85.[doi:10.3969/j.issn.1001-4616.2024.04.009]
　Liu Jie,Wang Yuanyuan,Guo Zhigang,et al.FEN1 Inhibitor SC13 Reverses the Drug Resistance of MCF-7/ADR Cells[J].Journal of Nanjing Normal University(Natural Science Edition),2024,(04):77-85.[doi:10.3969/j.issn.1001-4616.2024.04.009]
点击复制

FEN1抑制剂SC13逆转MCF-7/ADR细胞的耐药性研究()
分享到：

《南京师大学报（自然科学版）》[ISSN:1001-4616/CN:32-1239/N]

卷:
期数:
2024年04期
页码:
77-85
栏目:
生物学
出版日期:
2024-12-15

文章信息/Info

Title:
FEN1 Inhibitor SC13 Reverses the Drug Resistance of MCF-7/ADR Cells
文章编号:
1001-4616(2024)04-0077-09
作者:
刘 洁; 王源源; 郭志刚; 何凌峰
(南京师范大学生命科学学院,江苏分子与医学生物技术重点实验室,江苏 南京210023)
Author(s):
Liu Jie; Wang Yuanyuan; Guo Zhigang; He Lingfeng
(School of Life Sciences,Nanjing Normal University,Jiangsu Key Laboratory for Molecular and Medical Biotechnology,Nanjing 210023,China)
关键词:
乳腺癌; Flap核酸内切酶1; 阿霉素; 肿瘤治疗; 化疗耐药
Keywords:
breast cancer; FEN1; adriamycin; tumor treatment; chemoresistance
分类号:
R3F36H
DOI:
10.3969/j.issn.1001-4616.2024.04.009
文献标志码:
A
摘要:
癌细胞在化疗过程中产生的多药耐药性(multidrug resistance,MDR)仍然是目前临床治疗乳腺癌所面临的巨大挑战. 肿瘤细胞中强大的DNA损伤修复能力可能是导致其耐药性的主要原因之一. 研究发现,碱基切除修复(base excision repair,BER)途径中的关键蛋白Flap核酸内切酶1(FEN1)在耐阿霉素的人乳腺癌细胞(MCF-7/ADR)中高表达,并且FEN1抑制剂SC13可以显著增强阿霉素对于MCF-7/ADR的治疗敏感性,其具体的作用机制可能是通过cGAS-STING-NFκB信号通路激活了抗肿瘤免疫反应.
Abstract:
The development of multidrug resistance(MDR)in cancer cells during chemotherapy poses a significant challenge in the clinical treatment of breast cancer. One of the main contributors to drug resistance is the robust DNA damage repair capability of tumor cells. The research had revealed that Flap endonuclease 1(FEN1),a core protein involved in the base excision repair(BER)pathway,was highly expressed in adriamycin-resistant breast cancer cells. Moreover,the study found that the FEN1 inhibitor SC13 significantly enhanced the sensitivity of MCF-7/ADR cells to adriamycin. While the precise mechanism of action was not yet fully understood,it was hypothesized that the enhanced sensitivity of MCF-7/ADR cells may be attributed to the activation of potent antitumor responses mediated by the cGAS-STING-NFκB signaling pathways.

参考文献/References:

[1]PAN X,HONG X,LI S,et al. METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner[J]. Experimental & molecular medicine,2021,53(1):91-102.
[2]ALAMOLHODAEI N S,TSATSAKIS A M,RAMEZANI M,et al. Resveratrol as MDR reversion molecule in breast cancer:an overview[J]. Food and chemical toxicology,2017,103(3):223-232.
[3]KCIUK M,GIELECINSKA A,MUJWAR S,et al. Doxorubicin:an agent with multiple mechanisms of anticancer activity[J]. Cells,2023,12(4):659.
[4]WANG J,ZHOU L,LI Z,et al. YY1 suppresses FEN1 over-expression and drug resistance in breast cancer[J]. BMC cancer,2015,15(1):50.
[5]ZHENG L,JIA J,FINGER L D,et al. Functional regulation of FEN1 nuclease and its link to cancer[J]. Nucleic acids research,2011,39(3):781-794.
[6]YANG F,HU Z,GUO Z. Small-molecule inhibitors targeting FEN1 for cancer therapy[J]. Biomolecules,2022,12(7):1007.
[7]WU H,YAN Y,YUAN J,et al. miR-4324 inhibits ovarian cancer progression by targeting FEN1[J]. Journal of ovarian research,2022,15(1):32.
[8]ABDEL-FATAH T M,RUSSELL R,ALBARAKATI N,et al. Genomic and protein expression analysis reveals flap endonuclease 1(FEN1)as a key biomarker in breast and ovarian cancer[J]. Molecular oncology,2014,8(7):1326-1338.
[9]HE L,ZHANG Y,SUN H,et al. Targeting DNA flap endonuclease 1 to impede breast cancer progression[J]. EBiomedicine,2016,14(11):32-43.
[10]BUKOWSKI K,KCIUK M,KONTEK R. Mechanisms of multidrug resistance in cancer chemotherapy[J]. International journal of molecular sciences,2020,21(9):3233.
[11]AMIRI-KORDESTANI L,BASSEVILLE A,KURDZIEL K,et al. Targeting MDR in breast and lung cancer:discriminating its potential importance from the failure of drug resistance reversal studies[J]. Drug resistance updates,2012,15(1/2):50-61.
[12]SANCAR A,LINDSEY-BOLTZ L A,UNSAL-KACMAZ K,et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints[J]. Annu review of biochemistry,2004,73(1):39-85.
[13]SELVARAJAH J,ELIA A,CARROLL V A,et al. DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1[J]. Oncotarget,2015,6(1):427-440.
[14]SUNADA S,SAITO H,ZHANG D,et al. CDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity[J]. Biochemical and biophysical research communications,2021,550(2):56-61.
[15]ALLDAY M J,INMAN G J,CRAWFORD D H,et al. DNA damage in human B cells can induce apoptosis,proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective[J]. EMBO journal,1995,14(20):4994-5005.
[16]THOMAS C G,STROM A,LINDBERG K,et al. Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling[J]. Breast cancer research and treatment,2011,127(2):417-427.
[17]ZHANG T,TAN Y,ZHAO R,et al. DNA damage induced by oridonin involves cell cycle arrest at G2/M phase in human MCF-7 cells[J]. Contemporary oncology(pozn),2013,17(1):38-44.
[18]ZHANG R,ZHU L,ZHANG L,et al. PTEN enhances G2/M arrest in etoposide-treated MCF-7 cells through activation of the ATM pathway[J]. Oncology reports,2016,35(5):2707-2714.
[19]CAI X,CHIU Y H,CHEN Z J. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling[J]. Molecular cell,2014,54(2):289-296.
[20]LI X D,WU J,GAO D,et al. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects[J]. Science,2013,341(6152):1390-1394.
[21]WANG Y,LUO J,ALU A,et al. cGAS-STING pathway in cancer biotherapy[J]. Molecular cancer,2020,19(1):136.
[22]ZHAO Y,SIMON M,SELUANOV A,et al. DNA damage and repair in age-related inflammation[J]. Nature reviews immunology,2023,23(2):75-89.
[23]CHANUT R,PETRILLI V. Cytosolic DNA sensing by the cGAS-STING pathway in cancer[J]. Medical sciences(Paris),2019,35(6/7):527-534.
[24]MOTWANI M,PESIRIDIS S,FITZGERALD K A. DNA sensing by the cGAS-STING pathway in health and disease[J]. Nature reviews genetics,2019,20(11):657-674.
[25]DECOUT A,KATZ J D,VENKATRAMAN S,et al. The cGAS-STING pathway as a therapeutic target in inflammatory diseases[J]. Nature reviews immunology,2021,21(9):548-569.
[26]CHENG K,WANG X H,HUA Y T,et al. The tissue transglutaminase:a potential target regulating MDR in breast cancer[J]. European review for medical and pharmacological sciences,2020,24(11):6175-6184.
[27]LI J L,WANG J P,CHANG H,et al. FEN1 inhibitor increases sensitivity of radiotherapy in cervical cancer cells[J]. Cancer medicine,2019,8(18):7774-7780.
[28]HE L,LUO L,ZHU H,et al. FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer[J]. Molecular oncology,2017,11(6):640-654.
[29]PANTELIDOU C,SONZOGNI O,DE OLIVERIA T M,et al. PARP Inhibitor Efficacy depends on CD8(+)T-cell recruitment via intratumoral sting pathway activation in BRCA:deficient models of triple-negative breast cancer[J]. Cancer discovery,2019,9(6):722-737.
[30]CHABANON R M,MUIRHEAD G,KRASTEV D B,et al. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer[J]. Journal of clinical investigation,2019,129(3):1211-1228.
[31]STANISZEWSKA A D,ARMENIA J,KING M,et al. PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors[J]. Oncoimmunology,2022,11(1):2083755.

相似文献/References:

[1]龚乐君,张立鹏,李宇茜,等.基于决策树的乳腺癌病历文本的挖掘与决策[J].南京师大学报(自然科学版),2019,42(03):42.[doi:10.3969/j.issn.1001-4616.2019.03.006]
　Gong Lejun,Zhang Lipeng,Li Yuxi,et al.Mining and Decision-Making of Breast Cancer MedicalRecord Text Based on Decision Tree[J].Journal of Nanjing Normal University(Natural Science Edition),2019,42(04):42.[doi:10.3969/j.issn.1001-4616.2019.03.006]

备注/Memo

备注/Memo:
收稿日期:2023-07-19.
基金项目:国家自然科学基金项目(81872284).
通讯作者:何凌峰,博士,副教授,研究方向:DNA损伤修复. E-mail:lfhe22@139.com
更新日期/Last Update: 2024-12-15